NCT05896839 2026-03-18
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
National Cancer Institute (NCI)
Phase 1/2 Recruiting
Clinical Trials
28 trialsNCT04697576 2026-03-10
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT07422779 2026-02-20
MAK
Institute of Oncology Ljubljana
Phase NA Recruiting
NCT06999980 2026-02-19
Neo IRENIE
Melanoma Institute Australia
Phase 2 Recruiting
NCT06581406 2026-02-18
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Replimune Inc.
Phase 2/3 Recruiting
NCT07230613 2026-02-11
NEOREM-NEO-1
UNICANCER
Phase 2 Recruiting
NCT03340129 2026-02-02
ABC-X
Melanoma Institute Australia
Phase 2 Recruiting
NCT04562129 2026-01-29
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06365619 2026-01-29
NeoRelapse
University of Utah
Phase 2 Recruiting
NCT06295159 2026-01-08
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT05779423 2026-01-06
Cryoablation+Ipilimumab+Nivolumab in Melanoma
Massachusetts General Hospital
Phase 2 Recruiting
NCT05428007 2026-01-05
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
NYU Langone Health
Phase 2 Recruiting
NCT06794775 2025-12-12
SWE-NEO
Karolinska University Hospital
Phase 3 Recruiting
NCT04996823 2025-12-04
Axitinib + Ipilimumab in Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT07155317 2025-11-12
Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial
Emory University
Phase 2 Recruiting
NCT03017820 2025-10-08
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Phase 1 Recruiting
NCT06362369 2025-09-17
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Phase 1/2 Recruiting
NCT06624644 2025-09-10
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Linnaeus Therapeutics, Inc.
Phase 2/3 Recruiting
NCT06712927 2025-09-08
Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
Stanford University
Phase 2 Recruiting
NCT03646617 2025-08-13
RadVax
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT06377111 2025-07-14
A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma
University Health Network, Toronto
Phase 1 Recruiting
NCT04464759 2025-07-08
LIMIT
Abramson Cancer Center at Penn Medicine
Phase 1/2 Recruiting
NCT03645928 2025-06-19
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Iovance Biotherapeutics, Inc.
Phase 2 Recruiting
NCT06519266 2024-11-25
SCANDIUM-III
Vastra Gotaland Region
Phase 3 Recruiting
NCT06627595 2024-11-15
APiTOXMM
University Hospital, Montpellier
Recruiting
NCT03563729 2023-07-13
MEMBRAINS
Herlev Hospital
Phase 2 Recruiting
NCT03166397 2023-01-26
Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients
Sheba Medical Center
Phase 2 Recruiting